Mesoblast Ltd Total Assets
Mesoblast Ltd total assets. Based on the latest financial reports, Mesoblast Ltd (MESO) holds total assets worth $773.08 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see cash efficiency ratio of Mesoblast Ltd for how efficiently the company converts equity into cash flow.
Total Assets of Mesoblast Ltd (2005–2026)
Total assets of Mesoblast Ltd from 2005 to 2026. This chart illustrates how Mesoblast Ltd's total assets have evolved over time, based on quarterly financial data. See Mesoblast Ltd stock price for real-time trading data and today's change.
Mesoblast Ltd - Asset Composition Analysis
Mesoblast Ltd Total Assets Breakdown (June 2026)
Mesoblast Ltd total assets breakdown as of June 2026. Mesoblast Ltd's total assets of $773.08 Million consist of 25.6% current assets and 74.5% non-current assets. Explore Mesoblast Ltd (MESO) working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 6.1% |
| Accounts Receivable | $57.66 Million | 7.5% |
| Inventory | $28.11 Million | 3.6% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $431.92 Million | 55.9% |
| Goodwill | $134.45 Million | 17.4% |
Asset Composition Trend (2005–2026)
This chart illustrates how Mesoblast Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Mesoblast Ltd's current assets represent 25.6% of total assets in 2026, a decrease from 71.4% in 2005.
- Cash Position: Cash and equivalents constituted 6.1% of total assets in 2026, down from 70.3% in 2005.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 72.0% of total assets, an increase from 3.0% in 2005.
- Asset Diversification: The largest asset category is intangible assets at 55.9% of total assets.
Mesoblast Ltd Competitors by Total Assets
Key competitors of Mesoblast Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩925.44 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Shanghai Medicilon Inc
SHG:688202
|
China | CN¥2.88 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767
|
China | CN¥2.49 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥725.73 Million |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880
|
China | CN¥3.67 Billion |
Mesoblast Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.43 | 1.99 | 1.36 |
| Quick Ratio | 2.09 | 1.77 | 1.36 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $116.38 Million | $101.72 Million | $33.32 Million |
Mesoblast Ltd - Advanced Valuation Insights
This section examines the relationship between Mesoblast Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.69 |
| Latest Market Cap to Assets Ratio | 2.55 |
| Asset Growth Rate (YoY) | -1.5% |
| Total Assets | $773.08 Million |
| Market Capitalization | $1.97 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Mesoblast Ltd's assets at a significant premium (2.55x), suggesting investors see substantial growth potential or unique competitive advantages.
Slight Asset Contraction: Mesoblast Ltd's assets decreased by 1.5% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Mesoblast Ltd (2005–2026)
The table below shows the annual total assets of Mesoblast Ltd from 2005 to 2026.
| Year | Total Assets | Change |
|---|---|---|
| 2026-06-30 | $773.08 Million | -1.48% |
| 2025-06-30 | $784.68 Million | +17.27% |
| 2024-06-30 | $669.15 Million | -0.04% |
| 2023-06-30 | $669.41 Million | +1.10% |
| 2022-06-30 | $662.14 Million | -11.09% |
| 2021-06-30 | $744.72 Million | +1.52% |
| 2020-06-30 | $733.60 Million | +12.50% |
| 2019-06-30 | $652.12 Million | -5.82% |
| 2018-06-30 | $692.44 Million | +5.61% |
| 2017-06-30 | $655.69 Million | -4.14% |
| 2016-06-30 | $684.02 Million | -32.80% |
| 2015-06-30 | $1.02 Billion | +13.19% |
| 2014-06-30 | $899.31 Million | +1.77% |
| 2013-06-30 | $883.71 Million | +22.66% |
| 2012-06-30 | $720.46 Million | -5.61% |
| 2011-06-30 | $763.25 Million | +1831.56% |
| 2010-06-30 | $39.51 Million | +46.49% |
| 2009-06-30 | $26.98 Million | -2.93% |
| 2008-06-30 | $27.79 Million | +30.84% |
| 2007-06-30 | $21.24 Million | +29.62% |
| 2006-06-30 | $16.38 Million | -23.67% |
| 2005-06-30 | $21.47 Million | -- |
About Mesoblast Ltd
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers remestemcel-L-rknd, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid … Read more